Halozyme Therapeutics, Inc. (0J2O.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 8.14B |
| Enterprise Value | 10.2B |
| P/E Ratio | 23.97 |
| PEG Ratio | -1.7 |
| Price/Sales Ratio | 6.37 |
| Price/Book Ratio | -207.39 |
| Enterprise/Revenue | 7.6 |
| Enterprise/EBITDA | 17 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
| Profit Margin | 0.27 |
| Operating Margin | 0.56 |
| Return On Assets | 0.14 |
| Return On Equity | 5.44 |
| Revenue | 1.4B |
| Revenue/Share | 15.84 |
| Gross Profit | 1.09B |
| EBITDA | 904.34M |
| Net Income | 316.89M |
| Diluted EPS | 2.56 |
| Total Cash | 1.07B |
| Total Cash/Share | 9.44 |
| Total Debt | 3.25B |
| Total Debt/Equity | -58.84 |
| Current Ratio | 3.88 |
| Book Value Per Share | -0.49 |
| 52-Week Change | 44.1 |
| 52-Week High | 133.94 |
| 52-Week Low | 59.85 |
| Moving Average 50 Days | 115.06 |
| Moving Average 200 Days | 85.19 |
| Average Volume | 1,524 |
| Shares Outstanding | 114.01M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |